{"id":32348,"date":"2025-06-02T17:23:00","date_gmt":"2025-06-02T11:53:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32348"},"modified":"2025-06-02T11:24:37","modified_gmt":"2025-06-02T05:54:37","slug":"dry-eye-disease-treatment-landscape","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/dry-eye-disease-treatment-landscape","title":{"rendered":"Dry Eye Disease Treatment: A Growing Space with Expanding Therapeutic Options"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0493a979549\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0493a979549\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/dry-eye-disease-treatment-landscape\/#Currently_Available_Therapies_for_Dry_Eye_Disease_Treatment\" >Currently Available Therapies for Dry Eye Disease Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/dry-eye-disease-treatment-landscape\/#Dry_Eye_Disease_Treatment_Market_Evolves_with_TRYPTYRs_Regulatory_Milestone\" >Dry Eye Disease Treatment Market Evolves with TRYPTYR\u2019s Regulatory Milestone<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/dry-eye-disease-treatment-landscape\/#Promising_Dry_Eye_Disease_Therapies_on_the_Horizon\" >Promising Dry Eye Disease Therapies on the Horizon<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/dry-eye-disease-treatment-landscape\/#Where_is_the_Dry_Eye_Disease_Treatment_Market_Headed\" >Where is the Dry Eye Disease Treatment Market Headed?<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Dry eye disease (DED) is a common yet often underestimated condition affecting millions worldwide. Characterized by insufficient tear production or poor tear quality, it leads to persistent eye discomfort, irritation, and vision problems. Studies suggest that up to 30% of the adult population may experience some degree of dry eye symptoms, with prevalence increasing with age and certain environmental factors.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s analysis, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/dry-eye-disease-epidemiology-forecast\">diagnosed prevalent cases of DED<\/a> in the 7MM were <strong>~55 million<\/strong> in 2023. These cases are expected to increase at a significant CAGR throughout the study period (2020\u20132034). Mild cases of DED may be more common, as individuals with mild symptoms may not always seek medical attention. In contrast, moderate and severe cases, though less prevalent, can significantly impact quality of life. DelveInsight&#8217;s estimates project an increase in severity-specific DED cases over the coming years.<\/p>\n\n\n\n<p>Treating dry eye syndrome requires a combination of methods: using over-the-counter artificial tears, prescription drugs such as<strong> RESTASIS or XIIDRA<\/strong>, procedures like LipiFlow, lifestyle adjustments including using humidifiers and taking omega-3 supplements, and, for more severe cases, options like punctal plugs or scleral lenses. Identifying the condition early and starting treatment promptly can help avoid complications such as corneal ulcers and scarring.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-currently-available-therapies-for-dry-eye-disease-treatment\"><span class=\"ez-toc-section\" id=\"Currently_Available_Therapies_for_Dry_Eye_Disease_Treatment\"><\/span><strong>Currently Available Therapies for Dry Eye Disease Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Various drugs have gained approval in the United States, Europe, and Japan for treating and managing DED. These <a href=\"https:\/\/www.delveinsight.com\/report-store\/dry-eye-disease-market-insights\">dry eye disease drugs<\/a> include <strong>CEQUA <\/strong>(Sun Pharmaceutical), <strong>TYRVAYA <\/strong>(OYSTER POINT PHARMA), <strong>EYSUVIS <\/strong>(Alcon Labs\/Kala Pharmaceuticals), <strong>VEVYE <\/strong>(Novaliq\/Harrow Eye), and <strong>NOV03 <\/strong>(Bausch &amp; Lomb Incorporated\/Novaliq).&nbsp;<\/p>\n\n\n\n<p><strong>CEQUA (cyclosporine ophthalmic solution) 0.09%<\/strong>, developed by <strong>Sun Pharmaceutical<\/strong>, is a sterile, clear solution designed to boost tear production in patients with keratoconjunctivitis sicca. Taken twice daily, it functions as a calcineurin inhibitor and immunosuppressant, potentially reducing ocular inflammation and partially modulating the immune response to alleviate dry eye symptoms.<\/p>\n\n\n\n<p><strong>OYSTER POINT PHARMA<\/strong> offers <strong>TYRVAYA (varenicline solution) nasal spray<\/strong>, a prescription treatment for dry eye disease. Administered twice daily, it works by stimulating nicotinic acetylcholine receptors, activating the trigeminal parasympathetic pathway to increase basal tear production, thereby relieving dry eye discomfort. Viatris has finalized its acquisition of Oyster Point Pharma.<\/p>\n\n\n\n<p><strong>EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%<\/strong>, developed by <strong>Alcon Labs\/Kala Pharmaceuticals<\/strong>, is FDA-approved for short-term relief of dry eye disease symptoms. Employing Kala\u2019s AMPPLIFY Mucus-Penetrating Particle technology, it enhances penetration of loteprednol etabonate into eye tissues, providing rapid symptom relief with a strong safety profile.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/dry-eye-disease-market-insights\"><img decoding=\"async\" width=\"1024\" height=\"457\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112111\/Dry-Eye-Disease-Market-Key-Insights-1024x457.png\" alt=\"Dry-Eye-Disease-Market-Key-Insights\" class=\"wp-image-32353\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112111\/Dry-Eye-Disease-Market-Key-Insights-1024x457.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112111\/Dry-Eye-Disease-Market-Key-Insights-300x134.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112111\/Dry-Eye-Disease-Market-Key-Insights-150x67.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112111\/Dry-Eye-Disease-Market-Key-Insights-768x342.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112111\/Dry-Eye-Disease-Market-Key-Insights-1536x685.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112111\/Dry-Eye-Disease-Market-Key-Insights-2048x913.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p><strong>VEVYE<\/strong>, from <strong>Novaliq\/Harrow Eye<\/strong>, is an innovative dry eye treatment featuring cyclosporine solubilized in a water-free formulation. Approved by the FDA in June 2023, it delivers fast-acting relief without water, antimicrobial preservatives, oils, or surfactants. VEVYE is the first cyclosporine-based therapy targeting both signs and symptoms of dry eye disease, dosed as one drop twice daily per eye.<\/p>\n\n\n\n<p><strong>NOV03<\/strong>, developed by <strong>Bausch &amp; Lomb\/Novaliq<\/strong> and FDA-approved in 2023, is a water-free, preservative-free eye drop for dry eye disease linked to Meibomian gland dysfunction. Its unique mechanism stabilizes the tear film\u2019s lipid layer, reducing evaporation and possibly liquefying altered secretions. It is administered as one drop four times daily per eye, improving symptoms and showing good tolerability.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-dry-eye-disease-treatment-market-evolves-with-tryptyr-s-regulatory-milestone\"><span class=\"ez-toc-section\" id=\"Dry_Eye_Disease_Treatment_Market_Evolves_with_TRYPTYRs_Regulatory_Milestone\"><\/span><strong>Dry Eye Disease Treatment Market Evolves with TRYPTYR\u2019s Regulatory Milestone<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Six years after separating from Novartis and becoming a publicly traded company, eye care specialist <strong>Alcon <\/strong>has received its first FDA approval for a prescription dye eye disease medication. The approval is for <strong>TRYPTYR (acoltremon ophthalmic solution)<\/strong>, a <a href=\"https:\/\/www.delveinsight.com\/report-store\/dry-eye-disease-market-insights\">treatment for dry eye disease<\/a>.<\/p>\n\n\n\n<p>TRYPTYR is a novel TRPM8 receptor agonist designed to stimulate tear production and is administered as a single drop twice daily. This approval is based on data from two Phase III dry eye disease clinical trials involving over 930 patients with a history of DED, randomized equally to receive either TRYPTYR or a placebo vehicle.&nbsp;<\/p>\n\n\n\n<p>In the <strong>COMET-2 and COMET-3 studies<\/strong>, up to four times more patients treated with TRYPTYR showed at least a 10mm increase in natural tear production by Day 14 compared to those receiving the vehicle\u201442.6% versus 8.2% in COMET-2, and 53.2% versus 14.4% in COMET-3 (both with p-values less than 0.0001). These significant improvements were consistent through Day 90, with TRYPTYR showing a statistically meaningful increase in tear production as early as the first day of treatment.<\/p>\n\n\n\n<p>The approval of TRYPTYR has intensified the competition among the other pharma companies to bring their lead assets to the market.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-promising-dry-eye-disease-therapies-on-the-horizon\"><span class=\"ez-toc-section\" id=\"Promising_Dry_Eye_Disease_Therapies_on_the_Horizon\"><\/span><strong>Promising Dry Eye Disease Therapies on the Horizon<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The evolving <a href=\"https:\/\/www.delveinsight.com\/report-store\/dry-eye-disease-pipeline-insight\">dry eye disease drug pipeline<\/a> encompasses a diverse range of medications with innovative mechanisms, user-friendly administration, and enhanced safety and effectiveness. Several pharma companies are working on their lead candidates in various phases of development to improve the dry eye disease treatment landscape.&nbsp;<\/p>\n\n\n\n<p>Some of the dry eye disease drugs in the pipeline include <strong>PL9643 <\/strong>(Palatin Technologies), <strong>Reproxalap <\/strong>(Aldeyra Therapeutics, Inc.), <strong>Tivanisiran (SYL1001) <\/strong>(Sylentis\/PharmaMar), <strong>Tavilermide<\/strong> (Mimetogen), <strong>SkQ1 eye drops<\/strong> (Mitotech), <strong>BRM421 <\/strong>(BRIM Biotechnology), <strong>RGN-259 (T\u03b24)<\/strong> (ReGenTree\/RegeneRx Biopharmaceuticals), and others.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/dry-eye-disease-market-insights\"><img decoding=\"async\" width=\"1024\" height=\"448\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112142\/Emerging-Therapies-for-Dry-Eye-Disease-1024x448.png\" alt=\"Emerging-Therapies-for-Dry-Eye-Disease\" class=\"wp-image-32354\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112142\/Emerging-Therapies-for-Dry-Eye-Disease-1024x448.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112142\/Emerging-Therapies-for-Dry-Eye-Disease-300x131.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112142\/Emerging-Therapies-for-Dry-Eye-Disease-150x66.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112142\/Emerging-Therapies-for-Dry-Eye-Disease-768x336.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112142\/Emerging-Therapies-for-Dry-Eye-Disease-1536x672.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112142\/Emerging-Therapies-for-Dry-Eye-Disease-2048x896.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>The anticipated launch of these emerging therapies for dry eye disease treatment are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the dry eye disease treatment market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-where-is-the-dry-eye-disease-treatment-market-headed\"><span class=\"ez-toc-section\" id=\"Where_is_the_Dry_Eye_Disease_Treatment_Market_Headed\"><\/span><strong>Where is the Dry Eye Disease Treatment Market Headed?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The landscape of dry eye disease treatment across the 7MM is rapidly evolving. A wide range of options, including pharmaceutical drugs, in-office procedures, eye protection strategies, and surgical solutions, are crucial in managing DED. Market forecasts indicate robust growth, with the <a href=\"https:\/\/www.delveinsight.com\/report-store\/dry-eye-disease-market-insights\">DED market<\/a> in the 7MM expected to exceed <strong>USD 3.7 billion<\/strong> by 2023.<\/p>\n\n\n\n<p>The United States led the 7MM dry eye disease market in 2023, contributing approximately <strong>73%<\/strong> of the total market share, and is projected to maintain its dominant position moving forward. This sustained growth is largely driven by the anticipated launch of several new therapies currently in development.<\/p>\n\n\n\n<p>Additionally, the integration of diagnostic technologies for early detection and personalized treatment approaches is enhancing patient outcomes. Emerging markets are also contributing to demand growth as healthcare infrastructure improves globally.&nbsp;<\/p>\n\n\n\n<p>Overall, the dry eye disease market is headed toward more effective, targeted therapies combined with technological advancements, creating a dynamic and rapidly evolving landscape.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/dry-eye-disease-market-insights\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112041\/Dry-Eye-Disease-Market-Assessment-1024x194.png\" alt=\"Dry Eye Disease Market Assessment\" class=\"wp-image-32352\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112041\/Dry-Eye-Disease-Market-Assessment-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112041\/Dry-Eye-Disease-Market-Assessment-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112041\/Dry-Eye-Disease-Market-Assessment-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112041\/Dry-Eye-Disease-Market-Assessment-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112041\/Dry-Eye-Disease-Market-Assessment-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02112041\/Dry-Eye-Disease-Market-Assessment.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Dry eye disease (DED) is a common yet often underestimated condition affecting millions worldwide. Characterized by insufficient tear production or poor tear quality, it leads to persistent eye discomfort, irritation, and vision problems. Studies suggest that up to 30% of the adult population may experience some degree of dry eye symptoms, with prevalence increasing with [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":32350,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[18957,22563,21570,22562,22561],"industry":[17225],"therapeutic_areas":[17244],"class_list":["post-32348","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-dry-eye-disease","tag-dry-eye-disease-drugs","tag-dry-eye-disease-market","tag-dry-eye-disease-pipeline","tag-dry-eye-disease-treatment","industry-pharmaceutical","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Navigating the Dry Eye Disease Treatment Landscape<\/title>\n<meta name=\"description\" content=\"The dry eye disease treatment market is headed toward more effective, targeted therapies combined with technological advancements.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/dry-eye-disease-treatment-landscape\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Navigating the Dry Eye Disease Treatment Landscape\" \/>\n<meta property=\"og:description\" content=\"The dry eye disease treatment market is headed toward more effective, targeted therapies combined with technological advancements.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/dry-eye-disease-treatment-landscape\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-02T11:53:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02111932\/dry-eye-disease-treatment-landscape.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Navigating the Dry Eye Disease Treatment Landscape","description":"The dry eye disease treatment market is headed toward more effective, targeted therapies combined with technological advancements.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/dry-eye-disease-treatment-landscape","og_locale":"en_US","og_type":"article","og_title":"Navigating the Dry Eye Disease Treatment Landscape","og_description":"The dry eye disease treatment market is headed toward more effective, targeted therapies combined with technological advancements.","og_url":"https:\/\/www.delveinsight.com\/blog\/dry-eye-disease-treatment-landscape","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-06-02T11:53:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02111932\/dry-eye-disease-treatment-landscape.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/dry-eye-disease-treatment-landscape","url":"https:\/\/www.delveinsight.com\/blog\/dry-eye-disease-treatment-landscape","name":"Navigating the Dry Eye Disease Treatment Landscape","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/dry-eye-disease-treatment-landscape#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/dry-eye-disease-treatment-landscape#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02111932\/dry-eye-disease-treatment-landscape.png","datePublished":"2025-06-02T11:53:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The dry eye disease treatment market is headed toward more effective, targeted therapies combined with technological advancements.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/dry-eye-disease-treatment-landscape"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/dry-eye-disease-treatment-landscape#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02111932\/dry-eye-disease-treatment-landscape.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02111932\/dry-eye-disease-treatment-landscape.png","width":466,"height":284,"caption":"dry-eye-disease-treatment-landscape"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/02111932\/dry-eye-disease-treatment-landscape-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dry Eye disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dry Eye Disease Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dry Eye Disease Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dry Eye Disease Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dry Eye Disease Treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Dry Eye disease<\/span>","<span class=\"advgb-post-tax-term\">Dry Eye Disease Drugs<\/span>","<span class=\"advgb-post-tax-term\">Dry Eye Disease Market<\/span>","<span class=\"advgb-post-tax-term\">Dry Eye Disease Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Dry Eye Disease Treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 months ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Jun 2, 2025","modified":"Updated on Jun 2, 2025"},"absolute_dates_time":{"created":"Posted on Jun 2, 2025 5:23 pm","modified":"Updated on Jun 2, 2025 11:24 am"},"featured_img_caption":"dry-eye-disease-treatment-landscape","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32348"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32348\/revisions"}],"predecessor-version":[{"id":32355,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32348\/revisions\/32355"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32350"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32348"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32348"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}